Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Non‐serious adverse events · people with hepatocellular carcinoma

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 97 participants
Very low

Non‐serious adverse events (hand‐foot skin reaction) · people with hepatocellular carcinoma

Radioembolisation may leads to lower non‐serious adverse events (hand‐foot skin reaction) compared with sorafenib (low certainty).

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
RR 0.02 [0, 0.06]
2 studies · 734 participants
Low

Non‐serious adverse events (hyperbilirubinaemia: most frequent) · people with hepatocellular carcinoma

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 341 participants
Very low